NVAX.O
Latest Trade
4.03USDChange
0.05(+1.13%)Volume
1,365,721Today's Range
-
4.0952 Week Range
-
51.60As of on the NASDAQ ∙ Minimum 15 minute delay
Previous Close | 3.99 |
|---|---|
Open | 4.05 |
Volume | 1,365,721 |
3M AVG Volume | 17.73 |
Today's High | 4.09 |
Today's Low | 3.94 |
52 Week High | 51.60 |
52 Week Low | 3.54 |
Shares Out (MIL) | 26.58 |
Market Cap (MIL) | 105.91 |
Forward P/E | -0.73 |
Dividend (Yield %) | -- |
Novavax Posts Q3 Loss Per Share Of $0.74
Novavax Inc - EMA Concluded That Co Would Not Be Able To Use Conditional Marketing Authorization Pathway For Resvax In EU
Novavax Q2 Loss Per Share $1.69
Novavax, Inc. is a clinical-stage vaccine company focused on the discovery, development and commercialization of recombinant nanoparticle vaccines and adjuvants. The Company operates through developing recombinant vaccines segment. The Company, through its recombinant nanoparticle vaccine technology, produces vaccine candidates to respond to both known and newly emerging diseases. The Company's product pipeline focuses on a range of infectious diseases with vaccine candidates in clinical development for respiratory syncytial virus (RSV), seasonal influenza, pandemic influenza and the Ebola virus (EBOV). The Company's lead adjuvant for human applications, Matrix-M, is in a Phase I/II clinical trial for pandemic influenza H7N9 vaccine candidate. It is also testing Matrix-M in conjunction with its EBOV vaccine candidate in a Phase I clinical trial. It is developing additional pre-clinical stage programs in a range of infectious diseases, including Middle East respiratory syndrome (MERS).
Industry
Biotechnology & Drugs
Executive Leadership
James Francis Young
Independent Chairman of the Board
Stanley C. Erck
President, Chief Executive Officer, Director
John J. Trizzino
Senior Vice President, Chief Business Officer, Chief Financial Officer and Treasurer
Gregory M. Glenn
President, Research and Development
John A. Herrmann
Senior Vice President, General Counsel, Corporate Secretary
Price To Earnings (TTM) | -- |
|---|---|
Price To Sales (TTM) | 6.63 |
Price To Book (MRQ) | -- |
Price To Cash Flow (TTM) | -- |
Total Debt To Equity (MRQ) | -- |
LT Debt To Equity (MRQ) | -- |
Return on Investment (TTM) | -86.57 |
Return on Equity (TTM) | -72.33 |
Novavax Inc shares crashed 65 percent on Thursday after data showed its vaccine failed to prevent RSV disease, a leading cause of respiratory infections in infants, missing the main goal of a late-stage study.
Novavax Inc said on Thursday its vaccine to prevent RSV infection, a leading cause of a respiratory disease in infants, failed to meet the main goal of a late stage study.
* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:
* Q1 EARNINGS PER SHARE VIEW $-0.13 -- THOMSON REUTERS I/B/E/S
* NOVAVAX REACHES SIGNIFICANT ENROLLMENT MILESTONE IN THE PREPARE(TM) PHASE 3 TRIAL OF ITS RSV F VACCINE
* SAYS PUBLIC OFFERING OF 30.3 MILLION COMMON SHARES PRICED AT $1.65PER SHARE
* NOVAVAX PROVIDES CORPORATE UPDATE AND REPORT OF FOURTH QUARTER AND YEAR-END 2017 FINANCIAL RESULTS
* NOVAVAX PROMOTES JOHN J. TRIZZINO TO EXPANDED ROLE AS CHIEF BUSINESS OFFICER AND CHIEF FINANCIAL OFFICER
* SAYS PHASE 2 TRIAL OF NANOFLU VACCINE EXPECTED TO BEGIN IN Q3 OF 2018
* NOVAVAX INC FILES FOR MIXED SHELF OF UP TO $200 MILLION - SEC FILING Source text: (http://bit.ly/2zNiPwp) Further company coverage:
* NOVAVAX INC FILES PROSPECTUS SUPPLEMENT RELATES TO THE ISSUANCE AND SALE OF UP TO $75 MILLION OF COMMON STOCK -SEC FILING Source text: (http://bit.ly/2Edci1c) Further company coverage:
* NOVAVAX CONTINUES PHASE 3 TRIAL OF THE RSV F VACCINE FOR INFANTS VIA MATERNAL IMMUNIZATION AND PROVIDES UPDATE ON PHASE 1/2 TRIAL OF THE NANOFLU™ VACCINE Source text for Eikon: Further company coverage:
* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
* Q3 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
* Q2 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S
* Novavax announces positive topline data from phase 2 older adult trial and provides path forward for RSV F vaccine programs Source text for Eikon: Further company coverage:
* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S
* Q1 earnings per share view $-0.17 -- Thomson Reuters I/B/E/S Source text for Eikon: Further company coverage:
* Novavax reports fourth quarter and year-end 2016 financial results
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.